glp-1 receptor agonists effects on cardiovascular risk reduction and outcome trials: An update GLP-1 receptor agonists (GLP-1RAs): cardiovascular

Diabetol Metab Syndr 16 , 92 (2024)

[PMCID:PMC11043712]

When analysing trials with different durations separately, a statistically significant difference across groups was detected ( p = 0.01, Figure 2): a significant positive association of GLP1RA with the incidence of cancer was found in the trials lasting 52 weeks (MHOR 2.20, 95% CI [1.32, 3.64], p = 0.003, Figure 2), whereas the difference was not significant for trials with a duration between 53 and 103 weeks (MHOR 1.17, 95% CI [0.87, 1.56], Figure 2), and no difference was found between groups for trials lasting at least 104 weeks (MHOR 1.02, 95% CI [0.95, 1.10], Figure 2)

As more patients and healthcare providers seek effective diabetes management solutions with minimal side effects, demand for GLP-1 receptor agonists is set to surge